DK3484921T3 - Anti-IL-22R antistoffer - Google Patents

Anti-IL-22R antistoffer Download PDF

Info

Publication number: DK3484921T3
Authority: DK; Denmark
Prior art keywords: antibodies
Prior art date: 2016-07-15

Application number

DK17746011.0T

Other languages

English (en)

Inventor

Christophe Frederic Jerome Blanchetot

Birgitte Ursã¿

Tine Skak-Nielsen

Malene Bertelsen

Der Woning Sebastian Van

Michael Saunders

Haard Johannes Joseph Wilhelmus De

Original Assignee

Argenx Bvba

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-07-15

Filing date

2017-07-14

Publication date

2022-02-07

2017-07-14 Application filed by Argenx Bvba filed Critical Argenx Bvba

2022-02-07 Application granted granted Critical

2022-02-07 Publication of DK3484921T3 publication Critical patent/DK3484921T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

DK17746011.0T 2016-07-15 2017-07-14 Anti-IL-22R antistoffer DK3484921T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB1612337.4A GB201612337D0 (en)	2016-07-15	2016-07-15	Ant-il-22r antibodies
PCT/EP2017/067923 WO2018011420A1 (en)	2016-07-15	2017-07-14	Anti-il-22r antibodies

Publications (1)

Publication Number	Publication Date
DK3484921T3 true DK3484921T3 (da)	2022-02-07

Family

ID=56890507

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK17746011.0T DK3484921T3 (da)	2016-07-15	2017-07-14	Anti-IL-22R antistoffer

Country Status (27)

Country	Link
US (4)	US10696741B2 (da)
EP (2)	EP3484921B1 (da)
JP (1)	JP7163275B2 (da)
KR (2)	KR102571012B1 (da)
CN (1)	CN109641966B (da)
AU (1)	AU2017296094B2 (da)
BR (1)	BR112019000788A2 (da)
CA (1)	CA3024370A1 (da)
CY (1)	CY1125041T1 (da)
DK (1)	DK3484921T3 (da)
ES (1)	ES2903412T3 (da)
GB (1)	GB201612337D0 (da)
HR (1)	HRP20220197T1 (da)
HU (1)	HUE057615T2 (da)
IL (1)	IL264262B1 (da)
LT (1)	LT3484921T (da)
MX (1)	MX2019000539A (da)
MY (1)	MY197821A (da)
PL (1)	PL3484921T3 (da)
PT (1)	PT3484921T (da)
RS (1)	RS62884B1 (da)
RU (1)	RU2758721C2 (da)
SA (1)	SA519400856B1 (da)
SG (1)	SG11201900128XA (da)
SI (1)	SI3484921T1 (da)
UA (1)	UA125585C2 (da)
WO (1)	WO2018011420A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201612337D0 (en)	2016-07-15	2016-08-31	Argen-X N V	Ant-il-22r antibodies
JP7473977B2 (ja) *	2018-06-05	2024-04-24	バイオアトラインコーポレイテッド	抗ｉｌ２２抗体、抗体断片およびそれらの免疫コンジュゲートならびにそれらの使用
CN110302363B (zh) *	2019-07-04	2020-10-09	北京大学第三医院（北京大学第三临床医学院）	Il-22作为制备治疗pcos药物的应用及药物制剂
WO2023232789A1 (en)	2022-06-03	2023-12-07	Leo Pharma A/S	Liquid formulation of il-22r antibody
WO2024184333A1 (en)	2023-03-08	2024-09-12	Leo Pharma A/S	Il-22r antibody for use in treating atopic dermatitis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5892019A (en)	1987-07-15	1999-04-06	The United States Of America, As Represented By The Department Of Health And Human Services	Production of a single-gene-encoded immunoglobulin
AU2004223837C1 (en)	2003-03-24	2012-03-15	Zymogenetics, Inc.	Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
KR101238684B1 (ko) *	2004-10-22	2013-03-04	지모제넥틱스, 인코포레이티드	항-ｉｌ-22ｒａ 항체 및 결합 파트너 및 염증에서의사용방법
NZ621483A (en) *	2005-12-02	2015-10-30	Genentech Inc	Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
GB2461546B (en)	2008-07-02	2010-07-07	Argen X Bv	Antigen binding polypeptides
CN102665759B (zh) *	2009-11-19	2015-09-30	默克雪兰诺有限公司	人源化抗il-22ra抗体
GB2476681B (en)	2010-01-04	2012-04-04	Argen X Bv	Humanized camelid VH, VK and VL immunoglobulin domains
GB2504139B (en) *	2012-07-20	2014-12-31	Argen X Bv	Antibodies to highly conserved targets produced by the immunisation of Camelidae species
WO2013087914A1 (en) *	2011-12-16	2013-06-20	Synthon Biopharmaceuticals B.V.	EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
CA2878712A1 (en)	2012-08-31	2014-03-06	arGEN-X BV	Method for producing antibody molecules having inter-species, intra-target cross-reactivity
WO2014133728A2 (en) *	2013-03-01	2014-09-04	Albert Einstein College Of Medicine Of Yeshiva University	Hhla2 as a novel inhibitor of human immune system and uses thereof
CN105601739B (zh) *	2016-02-22	2019-01-18	王晨辉	一种人源化抗白介素22基因工程抗体及其应用
GB201612337D0 (en)	2016-07-15	2016-08-31	Argen-X N V	Ant-il-22r antibodies

2016
- 2016-07-15 GB GBGB1612337.4A patent/GB201612337D0/en not_active Ceased
2017
- 2017-07-14 BR BR112019000788A patent/BR112019000788A2/pt unknown
- 2017-07-14 ES ES17746011T patent/ES2903412T3/es active Active
- 2017-07-14 PT PT177460110T patent/PT3484921T/pt unknown
- 2017-07-14 MX MX2019000539A patent/MX2019000539A/es unknown
- 2017-07-14 SI SI201731037T patent/SI3484921T1/sl unknown
- 2017-07-14 AU AU2017296094A patent/AU2017296094B2/en active Active
- 2017-07-14 DK DK17746011.0T patent/DK3484921T3/da active
- 2017-07-14 IL IL264262A patent/IL264262B1/en unknown
- 2017-07-14 RS RS20220105A patent/RS62884B1/sr unknown
- 2017-07-14 KR KR1020197001500A patent/KR102571012B1/ko active IP Right Grant
- 2017-07-14 HU HUE17746011A patent/HUE057615T2/hu unknown
- 2017-07-14 JP JP2019501641A patent/JP7163275B2/ja active Active
- 2017-07-14 EP EP17746011.0A patent/EP3484921B1/en active Active
- 2017-07-14 LT LTEPPCT/EP2017/067923T patent/LT3484921T/lt unknown
- 2017-07-14 KR KR1020237028376A patent/KR20230128137A/ko active Application Filing
- 2017-07-14 UA UAA201901458A patent/UA125585C2/uk unknown
- 2017-07-14 RU RU2019103991A patent/RU2758721C2/ru active
- 2017-07-14 WO PCT/EP2017/067923 patent/WO2018011420A1/en unknown
- 2017-07-14 MY MYPI2018002752A patent/MY197821A/en unknown
- 2017-07-14 PL PL17746011T patent/PL3484921T3/pl unknown
- 2017-07-14 SG SG11201900128XA patent/SG11201900128XA/en unknown
- 2017-07-14 CN CN201780053328.1A patent/CN109641966B/zh active Active
- 2017-07-14 EP EP21208038.6A patent/EP4023674A3/en not_active Withdrawn
- 2017-07-14 HR HRP20220197TT patent/HRP20220197T1/hr unknown
- 2017-07-14 CA CA3024370A patent/CA3024370A1/en active Pending
2019
- 2019-01-08 US US16/242,760 patent/US10696741B2/en active Active
- 2019-01-10 SA SA519400856A patent/SA519400856B1/ar unknown
- 2019-10-23 US US16/661,783 patent/US11447544B2/en active Active
- 2019-10-23 US US16/661,757 patent/US11261246B2/en active Active
2022
- 2022-02-04 CY CY20221100099T patent/CY1125041T1/el unknown
- 2022-08-11 US US17/819,161 patent/US20230088269A1/en active Pending

Also Published As

Publication number	Publication date
IL264262A (en)	2019-02-28
US20200216528A1 (en)	2020-07-09
SA519400856B1 (ar)	2022-10-25
IL264262B1 (en)	2024-07-01
CN109641966B (zh)	2022-08-23
EP4023674A2 (en)	2022-07-06
US20190127459A1 (en)	2019-05-02
RU2758721C2 (ru)	2021-11-01
US20230088269A1 (en)	2023-03-23
RU2019103991A3 (da)	2021-04-29
CN109641966A (zh)	2019-04-16
WO2018011420A1 (en)	2018-01-18
KR102571012B1 (ko)	2023-08-24
ES2903412T3 (es)	2022-04-01
MY197821A (en)	2023-07-18
SI3484921T1 (sl)	2022-02-28
CY1125041T1 (el)	2023-03-24
US11261246B2 (en)	2022-03-01
HUE057615T2 (hu)	2022-05-28
KR20230128137A (ko)	2023-09-01
MX2019000539A (es)	2019-10-04
PT3484921T (pt)	2022-01-26
BR112019000788A2 (pt)	2019-07-02
CA3024370A1 (en)	2018-01-18
AU2017296094A1 (en)	2018-12-13
JP7163275B2 (ja)	2022-10-31
SG11201900128XA (en)	2019-02-27
RU2019103991A (ru)	2020-08-17
AU2017296094B2 (en)	2024-02-01
US11447544B2 (en)	2022-09-20
EP4023674A3 (en)	2022-10-05
EP3484921A1 (en)	2019-05-22
US10696741B2 (en)	2020-06-30
KR20190026766A (ko)	2019-03-13
US20200157207A1 (en)	2020-05-21
GB201612337D0 (en)	2016-08-31
RS62884B1 (sr)	2022-03-31
HRP20220197T1 (hr)	2022-04-29
JP2019528046A (ja)	2019-10-10
PL3484921T3 (pl)	2022-03-28
UA125585C2 (uk)	2022-04-27
EP3484921B1 (en)	2021-11-17
LT3484921T (lt)	2022-01-10

Publication	Publication Date	Title
DK3625259T3 (da)	2024-07-08	Anti-sirpalpha-antistoffer
DK3344654T3 (da)	2021-01-18	Anti-lag-3-antistoffer
DK3455257T3 (da)	2021-11-01	Anti-pd-l1-antistoffer
DK4050034T3 (da)	2024-06-03	Cd3-bindende antistoffer
KR102355950B9 (ko)	2023-10-26	Tigit에 대한 항체
DK3411404T3 (da)	2023-01-30	Psma- og cd3-bispecifikke t-celleinddragende antistofkonstruktioner
DK3411410T3 (da)	2021-06-07	Pd-1-antistoffer
DK3405050T3 (da)	2020-06-02	Børnesikret snusbeholder
DK3332006T3 (da)	2024-01-02	Hidtil ukendte anti-PD-L1-antistoffer
DK3350218T3 (da)	2024-04-02	Polyomavirus-neutraliserende antistoffer
KR20180085002A (ko)	2018-07-25	인간화된 항-cll-1 항체
DK3606961T3 (da)	2022-07-04	Garp-tgf-beta-antistoffer
DK3436823T3 (da)	2021-04-26	Antigen-array
DK3335532T3 (da)	2019-10-14	Tandharve
DK3452513T3 (da)	2024-07-15	Humaniserede anti-il-ir3-antistoffer
DK3250593T3 (da)	2022-08-22	Anti-transthyretin-antistoffer
DK3445708T3 (da)	2021-06-07	Stigbøjle
DK3402792T3 (da)	2021-11-15	Quinolin-2-on-derivater
DK3509963T3 (da)	2021-10-11	Pallecontainer
DK3528829T3 (da)	2022-05-30	Bacitracin-alginat-oligomer-konjugater
DK3484921T3 (da)	2022-02-07	Anti-IL-22R antistoffer
DK3575238T3 (da)	2022-01-31	Pallecontainer
ES2984636T3 (es)	2024-10-30	Anticuerpos anti-IL-5
ITUB20155097A1 (it)	2017-05-05	Anticorpi umanizzati anti-BAG3
DE112017006386A5 (de)	2019-08-29	Schraubarbeitszylinder